BioSpace - Targacept, Inc. News, Search Jobs, Events

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

Search the Site

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

..

Targacept, Inc.

200 East First Street
Suite 300
Winston-Salem North Carolina 27101-4165 U.S.A.
Phone: 336-480-2100 Fax: 336-480-2107

Targacept, Inc. is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacept's lead program, TC-5214, is being co-developed with AstraZeneca and is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentad™ to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies.

Targacept’s news releases are available on its website at www.targacept.com.

Key Statistics

Email: heather.savelle@targacept.com
Ownership: Public

Web Site: Targacept, Inc.
Employees: 120
Symbol: TRGT

Industry
Biopharmaceutical

Segment
Research and Development

Company News

Targacept, Inc. (TRGT) Announces Initiation of Phase 2b Study of TC-5214 in Overactive Bladder 5/29/2013 10:22:38 AM More...

Targacept, Inc. (TRGT) Reports First Quarter 2013 Financial Results 5/7/2013 8:13:14 AM More...

Targacept, Inc. (TRGT) Completes Recruitment in Phase 2b Trial of TC-1734 in Mild to Moderate Alzheimer's Disease 4/29/2013 12:25:48 PM More...

Targacept, Inc. (TRGT) Announces Participation in Upcoming Conferences 4/23/2013 6:35:24 AM More...

Targacept, Inc. (TRGT) Completes Recruitment in Phase 2b Schizophrenia Trial of TC-5619 4/18/2013 11:37:46 AM More...

Targacept, Inc. (TRGT) Announces Changes to Board of Directors and Management 3/19/2013 11:29:40 AM More...

Targacept, Inc. (TRGT) Restructures Collaboration With AstraZeneca PLC (AZN) 3/5/2013 7:45:45 AM More...

Targacept, Inc. (TRGT) to Present at the Cowen and Company 33rd Annual Health Care Conference 2/26/2013 7:09:55 AM More...

Targacept, Inc. (TRGT) Reports Fourth Quarter and 2012 Financial Results 2/14/2013 6:51:45 AM More...

Targacept, Inc. (TRGT) to Report Fourth Quarter and 2012 Financial Results on February 13, 2013 2/6/2013 7:00:56 AM More...

1